| Autor: |
Robert Waugh, Rebecca Lyon, Timothy Rowland, Kelly Byrne, Rebecca Crook, Michael Fisher, Sean Ewings, Megan Lawrence, Sujan Dilly-Penchala, Henry Pertinez, Laura Else, Helen Reynolds, Thomas Jaki, Rajith K. R. Rajoli, Richard Fitzgerald, Andrew Owen, Pavel Mozgunov, Lauren Walker, Saye Khoo, Colin Hale, Parys Hatchard, Karen Martin, Keira Fines, Izabela Eberhart, Alieu Amara, Lucy Johnson, Gareth Griffiths, David G. Lalloo, Tom Fletcher, Geoffrey Saunders, Michael Jacobs, Christie Woods |
| Rok vydání: |
2021 |
| Předmět: |
|
| Popis: |
Repurposing approved drugs may rapidly establish effective interventions during a public health crisis. This has yielded immunomodulatory treatments for severe COVID-19, but repurposed antivirals have not been successful to date because of redundancy of the target in vivo or suboptimal exposures at studied doses. Nitazoxanide is an FDA approved antiparasitic medicine, that physiologically-based pharmacokinetic (PBPK) modelling has indicated may provide antiviral concentrations across the dosing interval, when repurposed at higher than approved doses. Within the AGILE trial platform (NCT04746183) an open label, adaptive, phase 1 trial in healthy adult participants was undertaken with high dose nitazoxanide. Participants received 1500mg nitazoxanide orally twice-daily with food for 7 days. Primary outcomes were safety, tolerability, optimum dose and schedule. Intensive pharmacokinetic sampling was undertaken day 1 and 5 with Cmin sampling on day 3 and 7. Fourteen healthy participants were enrolled between 18th February and 11th May 2021. All 14 doses were completed by 10/14 participants. Nitazoxanide was safe and well tolerated with no significant adverse events. Moderate gastrointestinal disturbance (loose stools) occurred in 8 participants (57.1%), with urine and sclera discolouration in 12 (85.7%) and 9 (64.3%) participants, respectively, without clinically significant bilirubin elevation. This was self-limiting and resolved upon drug discontinuation. PBPK predictions were confirmed on day 1 but with underprediction at day 5. Median Cmin was above the in vitro target concentration on first dose and maintained throughout. Nitazoxanide administered at 1500mg BID with food was safe and well tolerated and a phase 1b/2a study is now being initiated in COVID-19 patients. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
